共 30 条
- [21] Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK StudyONCOLOGY, 2012, 83 (03) : 151 - 157Tsutsumi, SoichiIshibashi, KeiichiroUchida, NobuyukiOjima, HitoshiHosouchi, YasuoYashuda, NaokuniKigure, WakakoYamauchi, SatoruAsao, TakayukiIshida, HideyukiKuwano, Hiroyuki
- [22] Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyLANCET ONCOLOGY, 2014, 15 (06) : 569 - 579Price, Timothy J.Peeters, MarcKim, Tae WonLi, JinCascinu, StefanoRuff, PaulSuresh, Atilli SatyaThomas, AnneTjulandin, SergeiZhang, KathyMurugappan, SwaminathanSidhu, Roger
- [23] Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR TrialJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 3031 - +Qin, ShukuiLi, JinWang, LiweiXu, JianmingCheng, YingBai, YuxianLi, WeiXu, NongLin, Li-zhuWu, QiongLi, YunfengYang, JianweiPan, HongmingOuyang, XuenongQiu, WenshengWu, KaichunXiong, JianpingDai, GuanghaiLiang, HoujieHu, ChunhongZhang, JunTao, MinYao, QiangWang, JunyuanChen, JiongjieEggleton, S. PeterLiu, Tianshu
- [24] STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancerBMC CANCER, 2015, 15Chibaudel, BenoistBonnetain, FranckTournigand, Christophede Larauze, Marine Hugde Gramont, ArmandLaurent-Puig, PierrePaget, JeromeHadengue, AlexandraNotelet, DominiqueBenetkiewicz, MagdalenaAndre, Thierryde Gramont, Aimery
- [25] Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trialLANCET ONCOLOGY, 2018, 19 (05) : 660 - 671Xu, Rui-HuaMuro, KeiMorita, SatoshiIwasa, SatoruHan, Sae WonWang, WeiKotaka, MasahitoNakamura, MasatoAhn, Joong BaeDeng, Yan-HongKato, TakeshiCho, Sang-HeeBa, YiMatsuoka, HiroshiLee, Keun-WookZhang, TaoYamada, YasuhideSakamoto, JunichiPark, Young SukKim, Tae Won
- [26] A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trialCANCER MEDICINE, 2018, 7 (09): : 4217 - 4227Iwamoto, ShigeyoshiOoki, AkiraMorita, SatoshiHara, HirokiTanioka, HiroakiSatake, HironagaKataoka, MasatoKotaka, MasahitoKagawa, YoshinoriNakamura, MasatoShingai, TatsushiIshikawa, MasashiMiyake, YasuhiroSudo, TakeshiHashiguchi, YojiroYabuno, TaichiSakamoto, JunichiTsuji, AkihitoAndo, MasahikoYamaguchi, Kensei
- [27] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancerInvestigational New Drugs, 2017, 35 : 345 - 358M. ThomasP. SadjadianJ. KollmeierJ. LoweP. MattsonJ. R. TroutM. GarganoM. L. PatchenR. WalshM. BeliveauJ. F. MarierN. BoseK. GordenF. Schneller
- [28] S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 705 - 712Miyamoto, YujiTsuji, AkihitoTanioka, HiroakiMaekawa, SoichiroKawanaka, HirofumiKitazono, MasakiOki, EijiEmi, YasunoriMurakami, HidetsuguOgata, YutakaSaeki, HiroshiShimokawa, MototsuguNatsugoe, ShojiAkagi, YoshitoBaba, HideoMaehara, Yoshihiko
- [29] A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancerINVESTIGATIONAL NEW DRUGS, 2017, 35 (03) : 345 - 358Thomas, M.Sadjadian, P.Kollmeier, J.Lowe, J.Mattson, P.Trout, J. R.Gargano, M.Patchen, M. L.Walsh, R.Beliveau, M.Marier, J. F.Bose, N.Gorden, K.Schneller, F., III
- [30] CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialCANCER COMMUNICATIONS, 2019, 39Shi, YuankaiLi, JinXu, JianmingSun, YanWang, LiweiCheng, YingLiu, WeiSun, GuopingChen, YiguiBai, LiZhang, YipingHe, XiaohuiLuo, YiWang, ZhehaiLiu, YunpengYao, QiangLi, YuhongQin, ShukuiHu, XiaohuaBi, FengZheng, RongshengOuyang, Xuenong